Clinical Trial: A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07303803) titled 'A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus' on Dec. 11.

Brief Summary: This trial aims to evaluate the efficacy and safety of chiglitazar as a combination therapy for patients with MASH and T2DM.

Study Start Date: Jan. 01, 2026

Study Type: INTERVENTIONAL

Condition: MASH - Metabolic Dysfunction-Associated Steatohepatitis T2DM (Type 2 Diabetes Mellitus)

Intervention: DRUG: Chiglitazar Placebo

Chiglitazar Placebo 48mg/day

DRUG: Chiglitazar

Chiglitazar 48mg/day

DRUG: vitamin E

Vitamin E 100mg/three times a day

DRUG: Polyene Phosphatidyl choline

Polye...